George B Abercrombie's Net Worth
$7.14 Million
Who is George B Abercrombie?
George B Abercrombie has an estimated net worth of $7.14 Million. This is based on reported shares across multiple companies, which include ZIOPHARM ONCOLOGY INC, BIOCRYST PHARMACEUTICALS INC, Innoviva, Inc., Brickell Biotech, Inc., TRANZYME INC, and INSPIRE PHARMACEUTICALS INC.
SEC CIK
George B Abercrombie's CIK is 0001485939
Past Insider Trading and Trends
2010 was George B Abercrombie's most active year for acquiring shares with 13 total transactions. George B Abercrombie's most active month to acquire stocks was the month of February. 2021 was George B Abercrombie's most active year for disposing of shares, totalling 13 transactions. George B Abercrombie's most active month to dispose stocks was the month of April. 2021 saw George B Abercrombie paying a total of $263,144.21 for 132,667 shares, this is the most they've acquired in one year. In 2021 George B Abercrombie cashed out on 195,334 shares for a total of $1,513,331.30, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ZIOPHARM ONCOLOGY INC (TCRT) Snapshot price: $2.35
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 25K |
—
|
—
| 25K |
Apr 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
BIOCRYST PHARMACEUTICALS INC (BCRX) Snapshot price: $5.51
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +23.03% | 6.82K |
—
|
—
| 36.43K |
Jun 12
| |||
Form 4
| +130.15% | 16.75K |
—
|
—
| 29.61K |
Jun 13
| |||
Form 4
|
∞
| 12.87K |
—
|
—
| 12.87K |
Jun 7
| |||
Form 4
|
—
|
0
|
$7.18 | -$38,600.00 |
0
|
Scheduled
|
Apr 18
| ||
Form 4
|
—
|
0
|
$10.91 | -$75,900.00 |
0
|
Scheduled
|
Feb 15
| ||
Form 4
|
—
|
0
|
$7.80 | -$44,750.00 |
0
|
Scheduled
|
Nov 15
| ||
Form 4
|
—
|
0
|
$8.85 | -$62,150.00 |
0
|
Scheduled
|
Sep 15
| ||
Form 4
| -100.00% | -3.00K |
$8.98 | -$913,950.00 |
0
|
Sep 10
| |||
Form 4
|
—
|
0
|
$9.16 | -$65,300.00 | 3K |
Scheduled
|
Jul 15
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 25
| |||
Form 4
|
—
|
0
|
$8.27 | -$75,137.09 | 3K |
Scheduled
|
May 24
| ||
Form 4
| -70.00% | -7.00K |
$12.70 | -$88,900.00 | 3K |
May 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 2
| |||
Form 4
| +66.67% | 4K |
$1.71 | $6,840.00 | 10K |
Mar 31
| |||
Form 4
| +100.00% | 3K |
$6.19 | $18,570.00 | 6K |
Nov 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 4
|
∞
| 3K |
$1.23 | $3,690.00 | 3K |
Mar 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Innoviva, Inc. (INVA) Snapshot price: $15.62
Sr. VP & Chief Comm. Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -4.57% | -13.68K |
$14.09 | -$192,814.40 | 285.48K |
Scheduled
|
Aug 20 - Aug 21
| ||
Form 4
| -2.06% | -12.68K |
$14.50 | -$183,512.78 | 604.39K |
May 20 - May 21
| |||
Form 4
| +31.61% | 74.44K |
—
|
—
| 309.92K |
Mar 2
| |||
Form 4
| -9.07% | -23.50K |
$16.46 | -$386,920.00 | 235.47K |
Scheduled
|
Feb 20 - Feb 21
| ||
Form 4
| -3.21% | -8.57K |
$13.22 | -$113,370.02 | 258.65K |
Scheduled
|
Nov 20 - Nov 21
| ||
Form 4
| -1.07% | -2.89K |
$12.28 | -$35,440.08 | 267.22K |
Aug 20
| |||
Form 4
| -0.82% | -2.23K |
$11.86 | -$26,424.08 | 270.11K |
May 20
| |||
Form 4
| -1.95% | -5.36K |
$12.04 | -$64,474.20 | 269.84K |
Feb 20
| |||
Form 4
| +63.34% | 106.72K |
—
|
—
| 275.19K |
Jan 17
| |||
Form 4
| -0.75% | -1.27K |
$10.91 | -$13,888.43 | 168.47K |
Nov 20
| |||
Form 4
| -1.13% | -1.94K |
$11.79 | -$22,860.81 | 169.46K |
Aug 20
| |||
Form 4
| -0.74% | -1.28K |
$11.09 | -$14,150.84 | 171.4K |
May 20
| |||
Form 4
| -3.06% | -5.38K |
$12.28 | -$66,017.28 | 170.18K |
Feb 19
| |||
Form 4
| +111.59% | 92.59K |
—
|
—
| 175.55K |
Jan 14
| |||
Form 4
| +714.29% | 71.43K |
—
|
—
| 81.43K |
Jan 7
| |||
Form 4
|
∞
| 10K |
—
|
—
| 10K |
Jun 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Brickell Biotech, Inc. (FRTX) Snapshot price: $0.98675
CHIEF EXECUTIVE OFFICER
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
TRANZYME INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 7
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Oct 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||